Innovative Diagnostic Platform Siloam Biosciences offers a versatile and proven microfluidic platform, Optimiser™, supporting over 70 assays, which appeals to laboratories and institutions seeking flexible, cost-effective diagnostic solutions.

Point-of-Care Expansion With the TROVA® desktop system designed for single-patient use, there is a growing opportunity to target clinics, urgent care centers, and remote healthcare providers seeking speedy diagnostics at the point of care.

Strategic Development Siloam is actively developing multipatient, multiplexed systems under a contract with the National Cancer Institute, representing an opening for collaborations with government and research institutions focused on advanced diagnostic automation.

Emerging Market Presence Although a small company, Siloam's targeted innovation in immunoassay microfluidics positions it as a potential partner or supplier for larger diagnostic companies looking to incorporate or license cutting-edge platforms.

Funding and Growth Potential With current revenue between 1 million and 10 million dollars and ongoing development efforts, there are significant opportunities for investment or acquisition for organizations interested in expanding in the in-vitro diagnostics sector.